| Drug Type CAR-TILs, in vivo CAR-T therapy | 
| Synonyms- | 
| Target | 
| Action inhibitors | 
| Mechanism CLDN6 inhibitors(Claudin 6 inhibitors), HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China  | 01 Jan 2021 | |
| Brain Cancer | Phase 1 | China  | 01 Jan 2021 | |
| Breast Cancer | Phase 1 | China  | 01 Jan 2021 | |
| Colorectal Cancer | Phase 1 | China  | 01 Jan 2021 | |
| Liver Cancer | Phase 1 | China  | 01 Jan 2021 | |
| Lung Cancer | Phase 1 | China  | 01 Jan 2021 | 





